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Introduction
Much interest has been recently gained by the possibility of manipulating the host milieu with chemotherapy and in particular with cyclophosphamide (CTX), in order to synergize with adoptively transferred immune cells for anti-tumor purposes (1, 2) . Although historically regarded as immunosuppressive, CTX has been shown to act as a strong adjuvant for either adoptive or active immunotherapy when utilized with carefully defined dosages and combination modalities (1) (2) (3) (4) . Additionally, it has been shown that the therapeutic outcome of conventional chemotherapy depends on the activation of the immune system as a consequence of immunogenic apoptosis of cancer cells that, in turn, depends on the coordinated emission of specific signals from dying cancer cells (5, 6).
The synergistic anti-tumor efficacy of the combination of CTX and immunotherapy has long been studied in preclinical models (7) (8) (9) (10) , as well as in clinical trials (11-13), highlighting the multiple mechanisms underlying this paradoxical phenomenon, that include provision of "space" (14) , suppression of regulatory T-cells (15) , augmentation of tumor infiltration by lymphocytes, functional activation of B and T-cells and homeostatic proliferation (8, 9, 16, 17) .
In mouse models, type I interferon (IFN-I) was identified as an important mediator of CTX immunomodulation (8) . Subsequent studies showed that IFN-I was indeed induced in vivo by CTX and that this cytokine was responsible for the expansion of memory CD4 + and CD8 + T-cells (18) .
More recent data indicated that CTX can affect dendritic cell (DC) homeostasis (19) and can restore an activated polyfunctional helper phenotype in tumor-specific adoptively transferred CD4 + T-cells (20) through type I IFN-dependent mechanisms.
We also reported that the synergistic anti-cancer activity of chemotherapy and immunotherapy is associated to the induction of a "cytokine storm", occurring primarily in the bone marrow of treated mice. Up-regulated factors included GM-CSF and interleukin (IL)-1β, cytokines regulating homeostatic expansion and T-cell survival (IL-7, IL-15, IL-2, IL-21) and involved in the polarization towards a T helper (Th)1 type of immune response (IFN-γ) (17) . Genomic and for 5 days and 12-Gy total-body irradiation) followed by the adoptive transfer of autologous tumorinfiltrating lymphocytes (TIL) resulted in objective response rates of 70% in patients with metastatic melanoma refractory to standard therapies (13) . More recent data demonstrated that highdose CTX alone (4 g/m 2 ), as conditioning before the infusion of melanoma-specific CD8 + T-cell clones, determined long-term T-cell persistence, their acquisition of a central memory phenotype and, noticeably, a clinical benefit in 50% of metastatic melanoma patients (24).
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The present study aims at investigating for the first time the gene expression modulation after a single high-dose CTX administration in human PBMC and at identifying the mediators and mechanisms through which CTX conditions the host immune system to perceive and react to tumor antigens in chemoimmunotherapy strategies. Patients with hematologic malignancies, receiving high-dose CTX (3-4 g/m 2 ) for stem cell mobilization before SCT, were investigated.
Research. 
Materials and methods

Patients' characteristics, treatment and PBMC isolation
A single high dose of cyclophosphamide (CTX) (Endoxan, Baxter) (3-4 g/m 2 ) was administered as mobilization regimen before autologous haematopoietic stem cell transplant (SCT) to 1 plasma cell leukemia (PCL), 1 T-cell prolymphocytic leukemia (T-PLL) and 14 multiple myeloma (MM)
patients (Supplementary Table S1 ). Patients were treated at the Department of Hematology, Azienda Policlinico Umberto I, Sapienza University of Rome according to the principles set out in the WMA Declaration of Helsinki.
Blood samples were obtained after written informed consent. Heparinized blood was collected pre-therapy and 1, 2 and 5 days after CTX administration by venipuncture. After separation of plasma, PBMC were obtained using Lymphoprep density centrifugation (Nycomed AS, Norway).
Part of the cells was cryopreserved and part was lysed in RLT buffer for RNA extraction (Qiagen, Milano, Italy).
RNA isolation, labeling and hybridization
Total RNA was obtained by RNeasy purification according to the manufacturer's instructions (Qiagen). Amino-allyl modified antisense RNA (aRNA) was synthesized in two amplification rounds from 1 μg total RNA using the Amino Allyl MessageAmp™ II aRNA Amplification Kit (Ambion, Monza, Italy) and its quality was assessed with the 2100 Bioanalyzer (Agilent Technologies). aRNAs were coupled to monoreactive Cy3 or Cy5 dyes (GE Healthcare), fragmented (RNA Fragmentation Reagents, Ambion), mixed and co-hybridized overnight in humidifying chambers at 50°C onto prehybridizated microarray slides printed with 34,580 70mer
probes, representing 24,650 genes and 37,123 transcripts (Human Genome Oligo Set Version 3.0, Operon) (LaRiM, ISS, Rome, Italy). The platform has been submitted to the Gene Expression Omnibus (GEO) database (GPL15718).
Microarray data analysis
Scanning and image file processing were performed with GenePix® 4200A instrument (Axon Instruments) and the obtained data were filtered with BRB-ArrayTools (developed by Dr. Richard Simon and BRB-ArrayTools Development Team) to exclude spots below a minimum intensity (200), flagged and with diameters <25 μm. Data were normalized using Lowess Smoother. Only genes expressed in at least 70% of samples were analyzed in subsequent statistical analyses (all done using the log2-tranformed ratios). To verify the amplification of a single product, a melting curve was generated after every run.
Relative expression levels were calculated by the comparative cycle threshold (ΔΔC T ) method and were normalized by GAPDH expression as previously described (21).
Plasma protein levels determination by ELISA
The concentration of CXCL10/IP-10, CXCL8/IL-8, CCL2/MCP-1, BAFF/ TNFSF13B and CD163 in plasma was assessed with the ELISA-based assays Quantikine (R&D Systems). HB-EGF was analyzed with the Abnova ELISA kit (Abnova GmbH, Germany). Briefly, 50-100 μl of plasma was used in each assay, according to the manufacturers' instructions, and the absorbance of the developed color was determined using a microplate reader set to 450 nm. Cytokine concentrations were extrapolated from the standard curves generated using recombinant human proteins. 
Flow cytometry
Results
Gene expression profiling of PBMC in response to CTX
To analyze the impact of a single high-dose CTX administration on human PBMC gene expression and to elucidate the mechanisms through which this drug may influence the immune system, the response to CTX was analyzed in one T-cell prolymphocytic leukemia, one plasma cell leukemia and eight multiple myeloma patients (Supplementary Table S1 ). Microarray analysis was performed before (pre) and at different times (1, 2 and 5 days) after chemotherapy. The data discussed in this publication have been deposited in the NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE39324.
Statistically significant differentially expressed genes were identified by means of class comparison (BRB-ArrayTools) followed by hierarchical clustering analysis. To analyze the kinetic of the transcriptional response to CTX, we pooled altogether the 890 genes differentially expressed post-CTX (118 genes were modulated at more than one time point) and subjected them to hierarchical clustering analyses. As shown in Fig. 1B (unsupervised clustering of the samples), pre-treatment samples (d0) and samples taken 5 days following CTX administration (d5) were more similar to each other than samples taken at day 1 or 2. Fig. 1C (unsupervised clustering of the genes) shows that the genes modulated at day 2 have the tendency to show similar expression variations already at day 1 with a certain degree of intra-patient variability.
Moreover, the transcript levels of most of the genes modulated at day 1 and/or 2 reverted to pretreatment levels by day 5 in 3 out of 5 patients and remained differentially expressed in the Remarkably, the most significant (P≤0.05) biological process stimulated by CTX in patients' PBMC included immune response-related genes. Other significantly enriched biological functions were: response to other organisms, response to stress, response to biotic stimulus, catabolic process and cell death ( Table 1 ). The functional classification of down-regulated genes showed that the most significantly enriched biological classes included genes regulating metabolic processes, cell cycle, organelle organization, ribonucleoprotein complex biogenesis and biosynthetic processes (Table 1) same time, the transcript levels of factors implicated in antigen processing and presentation were augmented, including CIITA (class II, major histocompatibility complex, transactivator), CD68, three cathepsins (CTSC, CTSL1, CTSZ), the alpha-galactosidase GLA, the alpha-glucosidase GAA, the serine protease TPP1, NEU1, SLC11A1 (a late phagosomal protein) and LAMP-2 (lysosomalassociated membrane protein 2).
Also genes belonging to the tumor necrosis factor (TNF) superfamily, such as TNFRSF1A (TNF-α-Receptor 1), TNFSF13B (BAFF), playing a critical role in B-cell expansion/migration, and TNFRSF4 (OX40), important for antigen-specific T-cell expansion/survival, were up-regulated. In addition, CD97, an activation-induced antigen expressed by lymphocytes was induced by CTX (Supplementary Table S2 ). Table S2 ).
The expression of numerous genes associated with stress, cell death, DNA repair, autophagy and chemotherapy resistance was increased in patients' PBMC early after CTX treatment. Among them, BCL6, which controls DNA-damage response, survival, cell cycle and cytokine-signaling, DRAM (damage-regulated autophagy modulator), BBC3 (Bcl2-binding component 3), which is an essential mediator of p53-dependent and p53-independent apoptosis induced by DNA damage, BAX (Bcl2-associated X protein), TRIAP1, which prevents induction of apoptosis in response to low levels of DNA damage, XRCC1, which corrects defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents, BID (BH3 interacting domain death agonist), which is phosphorylated upon DNA damage and forms heterodimers either with the pro-apoptotic protein BAX or the anti-apoptotic protein Bcl-2 and Table 2) . Down-regulated pathways included "Spliceosome", "DNA replication", "Cell cycle", "Pyrimidine metabolism", "Aminoacyl-tRNA biosynthesis" and "Ubiquitin proteasome" (Table 2 ).
Altogether these results suggest that CTX induces biosynthetic/metabolic process and cell cycle arrest, as well as cell death as a consequence of its cytotoxic activity on PBMC, and that, at the same time, it stimulates the expression of genes involved in the perception of stressed and dead cells and of immunomodulatory genes, including type I IFN-related and p53-related genes.
Validation of the microarray results by real-time PCR
To validate the microarray results, the expression of selected genes was assessed by real-time PCR on the same patients analyzed by microarray ( Fig. 2A and 2B ) as well as on a second cohort of 6 multiple myeloma patients (Supplementary Table S1 and Fig. 2C ). In Fig. 2A treatment levels. The scavenger receptor MARCO showed a trend to increase 2 and 5 days post-CTX, while CLEC10A levels were significantly decreased ( Fig. 2A) . Moreover, significantly increased expression of IRF5 (involved in IFN-α transcriptional activation) and of BAFF was observed post-treatment ( Fig. 2A) . The correlation of microarray versus RT-PCR results is shown in Fig. 2B for the significant time points.
Previous gene expression analyses showed that also another alkylating agent, namely dacarbazine, induces the expression of type I IFN related genes and among them of CXCL10 (IP-10), a proinflammatory chemokine identified as part of the "core" IFN signature observed in PBMC of IFNα-treated melanoma patients and healthy individuals (30) . We therefore assessed by real-time PCR whether the expression of CXCL10 and of another inflammatory IFN-and stress-induced chemokine, namely CCL2 (MCP-1) (32), was modulated by CTX and not revealed by microarray analysis. Fig. 2A shows a trend to increased expression for both transcripts at day 2, even though statistical significance was not reached due to interpatient variability.
The analysis of the modulation of MARCO, CLEC10A, IRF5, BAFF, CXCL10 and CCL2 expression induced by CTX in a second set of patients further validated microarray and real-time PCR results (Fig. 2C) .
Rise of CXCL10, CCL2, IL-8 and BAFF plasma levels following CTX treatment
In order to further characterize the inflammatory response to CTX, the variations of CXCL10, CCL2 and IL-8 plasma levels were assessed at different times after CTX administration. Moreover, we analyzed the modulation of BAFF, HB-EGF and of the soluble form of CD163.
As shown in Fig. 2B, CXCL10 and BAFF plasma levels were significantly (P≤0.05) raised 2 and 5 days following CTX administration, while CCL2 was significantly increased 5 days after chemotherapy and IL-8 plasma levels were augmented at day 2 and returned to baseline levels by day 5. On the contrary, HB-EGF and soluble CD163 levels were not affected by treatment.
These data not only validate at the protein levels some of the changes observed in gene expression both by microarray analysis and/or by real-time PCR, but also further expanded this information pointing to the inflammatory milieu resulting from damage in self tissues induced by chemotherapy.
Immunophenotype of monocytes, DCs and T lymphocytes
In order to characterize the effect of CTX on numbers of circulating DCs, monocytes and T lymphocytes and on their expression of markers selected on the basis of the microarray results, a multiparametric flow cytometric analysis was carried out in all assessable patients.
The white blood cell (WBC) count before and after treatment showed, as expected, that highdose CTX was indeed strongly leukotoxic, inducing a significant (P=0.009) WBC decline already at day 2 (Fig. 3A) . Remarkably, lymphocytes and monocytes showed different kinetics of depletion, with lymphocytes declining more rapidly (starting at day 1) (P=0.008) than monocytes. At day 2, when lymphocytes were 3.5 times less than pre-treatment levels (P=3.6x10 -5 ), monocytes showed only a 1.5-fold decrease (P=0.002) (Fig. 3A) . Accordingly, FACS analysis showed that the relative percentage of CD14 + monocytes in PBMC increased at day 1 and diminished at day 5 (P=0.05), while the relative percentage of CD3 + lymphocytes increased at day 5 ( Fig. 3B and 3C ), suggesting that some of the observed modulations in PBMC transcript levels may represent the signature of a cell type whose relative percentage in PBMC is changing. The proportion of cDC in PBMC did not change following treatment (Fig. 3B) , confirming previous data of DC resistance to CTX toxicity (19) . (Fig. 4A) . Moreover, although the percentage of monocytes expressing HLA-DR did not change following CTX in either subset (Fig. 4B) , an enhancement of its mean fluorescence
intensity (MFI) was observed at day 5, particularly in CD14 ++ CD16 -monocytes (P=0.05) ( Fig. 4A and Supplementary Fig. S2B ). In addition, the percentage of CD14 ++ CD16 -expressing either the scavenger receptor MARCO or the receptor for IL-8 (IL8RA) were significantly augmented 2 days following CTX administration (P=0.029) (Fig. 4B and Supplementary Fig. S2A ). The percentage of CD14 + CD16 + monocytes expressing the same markers showed a tendency to increase at day 5 ( Fig.   4B and Supplementary Fig. S2A ). The expression of the IL-17 receptor (IL17RA) did not change at any time point.
The effect of CTX on the expression of selected markers in cDCs is shown in Fig. 4C . The percentage of MARCO-expressing cDCs was augmented 5 days post-CTX administration (P= 0.05), while the proportion of cDCs expressing DCIR, HLA-DR and IL17RA was not influenced by treatment. As for monocytes, a trend to enhanced MFI of HLA-DR was observed in cDC at day 5 (Fig. 4C ). 
CD8
-T-cells expressing the costimulatory molecule OX40 (P=0.048), the activation marker CD69 (P=0.017) and IL8RA was observed at day 5 (Fig. 4D ). In the CD8 + subset, OX40 + cells showed a significant increase at day 5 (P=0.035), while IL-8RA + cells were raised at day 1 (P=0.014) ( Fig. 4D and Supplementary Fig. S2C ). The frequency of cells expressing IL17RA did not change at any time point.
Taken together these data show that the transcriptional profile induced by a drug like CTX on whole PBMC may be the result of both the variation in the relative percentage of different leukocyte subpopulations and signatures of given markers, whose expression is modulated in a given subpopulation, opening therefore novel unknown mechanistic hypotheses that will be discussed hereafter.
Discussion
Understanding the complex mechanisms responsible for the positive interactions between chemotherapy and immunotherapy is crucial to improve synergisms between the two treatments and to turn weak immunotherapeutic interventions into potent anti-cancer tools.
Until recently, the efficacy of a chemotherapeutic treatment prior to the adoptive transfer of cells of the immune system was believed to mainly rely on the induction of lymphopenia, that creates "room" for tumor-specific lymphocytes (14) , or on the selective depletion of Tregs (15) . We had shown in mouse models that CTX-mediated immunomodulation is multifactorial and that high throughput technologies may help the comprehension of such a complex phenomenon (21).
Consistently with such view, the present study was designed to unravel the multiple factors underlying the ability of high-dose CTX to potentiate immunotherapy in cancer patients. We report here that a single CTX injection rapidly (1-2 days) induces an extensive transcriptional modulation in PBMC of patients with hematologic malignancies, leading on the one hand to the reduction of cell cycle and biosynthetic/metabolic processes, as expected by an anti-cancer agent, and, on the other hand, to augmented transcript levels of cell death-, DNA damage-, stress-and immune system-related genes, including those related to type I IFN response. Moreover, microarray analysis pointed out a signature of apoptotic cell death. Although apoptosis was previously described as an immunologically silent cell-death modality, it is now recognized that the anti-tumor efficacy of certain chemotherapeutics depends on the induction of immunogenic apoptosis of tumor cells, through calreticulin exposure (33) and HMGB1 release (34) . Studies on mouse models from our group had shown that CTX induces immunogenic apoptosis of tumor cells (19) .
Several reports have shown that stress-induced cell death may produce exposure or release of danger signals and that the perception of them may alert the host, leading to a sterile inflammatory response (35, 36) . According to Matzinger's "danger model", endogenous non-foreign alarm signals include DNA, RNA, heat shock proteins, proinflammatory cytokines and IFN-α (37). The present microarray data showed that CTX exposure induces increased transcript levels of several Pathway analyses also showed that, upon CTX treatment, several transcripts of the p53 signaling pathway (known to be involved in DNA damage repair, cell cycle arrest and apoptosis) are augmented. Remarkably, it has been shown that IFN-α/β signaling contributes to boosting p53 responses to stress signals (38) , suggesting that IFN renders cells more susceptible to p53-dependent apoptosis in response to DNA-damaging agents. More recently, it was shown that p53, in turn, can enhance IFN signaling, thus contributing to innate immunity, most likely through the upregulation of IRF7 and IRF5 (39, 40) , which were indeed augmented in response to CTX.
Interestingly, IRF5 has been indicated as the master regulator of macrophage commitment to the M1 lineage, characterized by proinflammatory cytokine production (41). Therefore, it is possible to speculate that p53 activation and type I IFN signaling may cooperate to facilitate, on the one hand, CTX-mediated apoptosis and, on the other hand, a potent stimulation of the innate immunity. These results also suggest a possible positive interaction between type I IFN and CTX in potentiating antitumor immune responses, as previously shown in tumor models (18, 19) .
Noticeably, ELISA showed that CXCL10 and BAFF (type I IFN-induced genes) were augmented in the patients' serum along with the inflammatory mediators CCL2 and IL-8. CXCL10, indeed, was shown to be induced by the combination of IFN-α and peptide-based vaccination in monocytes of melanoma patients showing disease stabilization (42) . CXCL10 was also identified as part of the "core" IFN signature observed in PBMC of IFN-α-treated melanoma patients and healthy individuals (30) . CCL2 (MCP-1), on the other hand, is one of the key chemokines regulating migration of monocytes/macrophages to areas of inflammation (32) . Furthermore, along with IL-8, CCL2 has been shown to be secreted in response to apoptotic bodies in the course of 
Of particular relevance, all the above described immunoadjuvant effects of CTX were shown to be early and transient. Accordingly, the anti-tumor effectiveness of chemotherapy and immunotherapy combination has been shown to depend on the rapid sequential administration of the two treatments in mouse models (21). On the basis of the results reported herein, new therapeutic strategies may be hypothesized for the treatment of aggressive diseases, such as resistant solid tumors as well as hematologic malignancies relapsed after an allogeneic SCT, for which DLI alone is successful in a minority of patients. A CTX-based chemotherapy followed by adoptive immunotherapy or DLI with a precise timing and combination modalities may therefore represent the treatment of choice for these patients. 
